NYSEHealth CareMedical Instruments & SuppliesSnapshot 2026-07-07
Reading WST? This analysis is rebuilt every market day. Get it tracked free. No credit card.
Track WST free→QuarterlyIQ Insights · WST
Price, fair value, and the multiples that frame it on the same time axis. Scroll over the price chart to zoom.
Daily closes. Earnings/event dots inline.
A consensus fair price across 13 valuation methods, at three horizons. Current price $356.08. As of 2026-07-08. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
A long-thesis check that carries the widest uncertainty of the three horizons.
Top 10% on quality vs scored peers
Direction of the business behind the multiple. Bands are backend reads; trailing-12-month basis.
We take the 12-month fair value above and grade our own number — how the market prices this name versus what we'd justify, and where the two diverge.
At $356 the market pays 45× p/e — above the 30× p/e peer median but in line with its own 41× history. That premium reflects a durable franchise our peer-anchored $264 fair value understates; treat the 'expensive vs peers' read with medium confidence. Analysts target $310–$410. Note: our $264 fair value sits below the entire analyst range ($310–$410). The flat-multiple read looks rich, but earnings are inflecting up — trailing growth is accelerating and forward estimates confirm — so we've softened our read rather than brand an accelerating name expensive. Even valued only for durable growth at sustainable margins, it's worth about $395 — above today's price, so the premium reflects that growth case, not pure multiple expansion. Not investment advice.
$310.00 – $410.00 (median $390.00) · 5 analysts · as of 2026-07-06
One valuation read at a 12-month horizon, plus how price compares to peers and the company's own history.
Only weak execution quality — not the full expensive x weak x turbulent stack. Regime (Mania) does not concentrate fragility.
For similar setups historically (n=20,154): about 33% saw a 20%+ drawdown, and roughly 76% of those did not recover within the year. These are historical base rates for the cohort, not a forecast of this stock.
At today's price the business can't be justified by any reasonable horizon of the forecast growth; the price already runs past what the model can underwrite. These describe the expectations embedded in the price, not a forecast of the move. Reverse-DCF base: $5.16/sh owner earnings.
Looks more expensive than peers.
Around its own typical valuation.
Trailing four: 2025-Q1, 2025-Q2, 2025-Q3, 2026-Q1
Score 100 = cheapest in the cohort, 0 = richest. Bars are filled left-to-right based on the peer-relative score (or PEG/self-history where shown).
Direction of the business behind the multiple. Bands are backend reads; trailing-12-month basis.
Each method's implied share price per horizon. Provisional rows use a projected (historical-CAGR) growth input rather than analyst or management guidance.
| Method | Horizon | Est. price | Multiple | Per-share input | EPS source | Confidence |
|---|---|---|---|---|---|---|
| analyst target | 12M | $390.00 | — | — | Analyst | high |
| dcf fcfe | 12M | $117.20 | — | — | Hist. CAGR | high |
| dcf fcff | 12M | $121.93 | — | — | Hist. CAGR | high |
| graham number | 12M | $85.85 | — | — | TTM | high |
| Mgmt guidance | 12M | $253.42 | 29.6 | 8.57 | Mgmt | high |
| Peer EV/EBITDA | 12M | $154.13 | 14.0 | 10.70 | TTM | high |
| Peer P/FCF | 12M | $174.72 | 27.6 | 6.33 | TTM | high |
| Peer P/E | 12M | $234.36 | 29.6 | 7.93 | TTM | high |
| Peer P/S | 12M | $118.44 | 2.7 | 44.49 | TTM | high |
| PEG | 12M | $281.39 | 35.5 | 7.93 | TTM | high |
| residual income | 12M | $58.81 | — | — | TTM | high |
| Own P/E history | 12M | $328.82 | 41.5 | 7.93 | TTM | high |
| triangulated | 12M | $255.87 | 29.6 | 8.66 | Triangulated | high |
| Mgmt guidance | 3Y | $369.73 | 29.6 | 12.51 | Mgmt(prov.) | medium |
| Peer P/FCF | 3Y | $195.18 | 27.6 | 7.07 | Hist. CAGR(prov.) | medium |
| Peer P/E | 3Y | $296.66 | 29.6 | 10.04 | Analyst | medium |
| Peer P/S | 3Y | $136.63 | 2.7 | 51.32 | guidance | medium |
| PEG | 3Y | $356.20 | 35.5 | 10.04 | Analyst | medium |
| Own P/E history | 3Y | $416.24 | 41.5 | 10.04 | Analyst | medium |
| Mgmt guidance | 5Y | $475.61 | 29.6 | 16.09 | Mgmt(prov.) | high |
| Peer P/FCF | 5Y | $210.13 | 27.6 | 7.61 | Hist. CAGR(prov.) | high |
| Peer P/E | 5Y | $315.65 | 29.6 | 10.68 | Analyst | high |
| Peer P/S | 5Y | $145.38 | 2.7 | 54.61 | guidance | high |
| PEG | 5Y | $379.01 | 35.5 | 10.68 | Analyst | high |
| Own P/E history | 5Y | $442.88 | 41.5 | 10.68 | Analyst | high |
A “consensus-then vs. actual-now” overlay is on the way — what our valuation estimate said on a past date versus where the price actually landed.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
